HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
研究单位：[1]Daiichi Sankyo,Inc.[2]University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute Sichuan Provincial Tumor Hospital Chengdu,China,610041[3]Highlands Oncology Springdale,Arkansas,United States,72762[4]City of Hope Duarte,California,United States,91010[5]Moores Cancer Center at the UC San Diego Health La Jolla,California,United States,92037[6]Scripps MD Anderson Cancer Center La Jolla,California,United States,92037[7]USC Norris Comprehensive Cancer Center Los Angeles,California,United States,90033[8]Kaiser Permanente - Vallejo Medical Center Vallejo,California,United States,94589[9]Innovative Clinical Research Institute Whittier,California,United States,90603[10]Sarah Cannon/Florida Cancer Specialists - FCS South Port Charlotte,Florida,United States,33980
研究目的：
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
